<DOC>
	<DOCNO>NCT00113503</DOCNO>
	<brief_summary>This study compare two different dose method azathioprine ( IMURAN ) participants Crohn 's disease currently take steroid ( e.g . prednisone budesonide ) start steroid . The study 54 week long . All participant enrol receive active drug . Participants take dos either base upon weight base patient 's ability breakdown drug ( monitor 6-thioguanine nucleotide ( 6-TGN ) metabolite level blood ) . All patient enrol study receive active study drug .</brief_summary>
	<brief_title>Imuran Dosing Crohn 's Disease Study</brief_title>
	<detailed_description>This multi-center , double blind ( patient doctor know treatment group assignment ) , randomize ( patient put 1 2 group ) clinical trial compare two 52-week-long azathioprine ( AZA ) dose method . The patient enrol take steroid ( prednisone budesonide ) prescribe steroid . The patient either remission steroid , taper without flare , patient steroid still Crohn 's symptom , patient need start take steroid . After two week screen period , patient fit enrollment criterion begin take study drug . Patients begin taper steroid per set schedule , taper steroid completely week 13 . Patients need go back steroid return symptom allow , per set schedule protocol . Patients monthly visit include physical exam , blood test quality life questionnaire . Patients required keep diary abdominal pain , liquid soft stool general well . After 6 month , patient remission ( patient steroid , active symptom ) allow continue last 6 month study . Study visit last 6 month every 2 month , include physical exam blood test , quality life questionnaire . Patients study may receive dose change , require additional blood test safety .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>1070 yearsold. , Weigh 20100 kg ( 44220 lb ) . CD ileum , colon ileocolon , verify colonoscopy , barium enema , small bowel series perform within 36 month Perianal fistula eligible provide perianal disease account preponderance symptom . Have steroiddependent , steroidrefractory steroid naive CD . Steroiddependent CD : CDAI mCDAI &lt; 150 receive prednisone 1040 mg/day budesonide 39 mg/day least 12 week prior screen , unable taper prednisone 10 mg/day budesonide 3 mg/day without experience flare within previous 6 month . Steroids must stable dose 2 week prior screen ( week # 2 ) , prednisone dose 1040 mg/day budesonide dose 39 mg/day . Steroidrefractory CD : currently moderately active CD ( CDAI mCDAI 200 450 ) despite treatment 40 kg ) 0.5 mg/kg/day ( weigh 20 mg/day ( weigh prednisone &lt; 40 9 mg/day previous 4 week prior screen kg ) , budesonide evaluation . Prednisone budesonide must stable dose 2 week prior screen ( week # 2 ) . Steroidnaïve CD : currently moderately active CD , ( CDAI mCDAI 200 450 ) one following : 1 . Despite treatment aminosalicylates and/or antibiotic previous 4 week prior screen evaluation , candidate prednisone budesonide . 2 . Not currently therapy , candidate prednisone budesonide 3 . Patients prior exposure steroid , treat steroid 4 week prior screen , candidate prednisone budesonide Prednisone budesonide start screen visit , dose 40 mg/day 9 mg/day taper per steroid taper . Patients start steroid 14 day prior screen also qualify steroid naïve , however patient need 40 mg prednisone 9 mg budesonide . Discontinue oral rectal 5Aminosalicylic acid ( 5ASA ) therapy , rectal steroid , ciprofloxacin metronidazole screen visit . CDAI &gt; 450 CD require hospitalization intravenous ( iv ) corticosteroid , iv antibiotic total parenteral nutrition ( TPN ) . TPN enteral nutrition &gt; 1000 Calories/day ( TPN elemental diet impact CDAI ) . History resection 100 cm small bowel , total proctocolectomy , subtotal colectomy ileorectal anastomosis Ileostomy colostomy Severe fix symptomatic stenosis small large intestine Blood transfusion within 3 month screen Treatment 6MP AZA within 6 month prior screen Immunosuppressants biologics 3 month screen Treatment 2 week screening : Allopurinol ; Trimethoprimsulfamethoxazole ; NSAIDs aspirin &gt; 81mg/day ; Cholestyramine drug interfere enterohepatic circulation ; Furosemide thiazide diuretic ; Fishoil preparation . Discontinue use screening : Oral rectal 5ASA , rectal steroid , metronidazole quinolones Any prior treatment natalizumab Presence abnormal laboratory parameter : Carriage hepatitis B surface antigen positive hepatitis C antibody Lack one acceptable form contraception receive AZA Low TPMT activity</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Inflammatory Bowel Disease , Crohn 's disease , Crohn 's Colitis</keyword>
</DOC>